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Summary Recent evidence suggests that Staphylococcus aureus enterotoxins (SAEs)
could modify airway disease by acting as superantigens, an immune response that
can be monitored by detection of IgE antibodies to SAEs. We studied the expression
of total IgE and specific IgE to SAEs using the Uni-CAP system in healthy controls,
smokers without COPD and COPD patients. Only 1/10 controls (10%) and 1/16
smokers (6.3%) had IgE to SAEs compared to 7/18 patients with stable COPD (38.9%)
and 21/54 patients with exacerbated COPD (38.9%). The IgE levels to SAEs of the
patients with stable COPD (0.18 [0.05–26.2]kUA/l) and the patients with
exacerbated COPD (0.09 [0.05–18.6]kUA/l) were significantly higher than those of
smokers (n ¼ 16; 0.05 [0.05–0.82]kUA/l) and controls (n ¼ 11; 0.05 [0.05–0.9]kUA/l,
Po0:05). IgE to SAEs decreased significantly in the exacerbated patients during
hospitalization (0.13 [0.05–18.3] vs. 0.05 [0.05–11]kUA/l, Po0:001) going along with
a significant increase in FEV1 (38.1 [16.9–79.5] vs. 51.6 [15–80]%predicted,
Po0:001).Similarly to severe asthma, we found significantly elevated IgE to SAE in
COPD patients. Our data for the first time suggest differences between healthy
subjects, smokers and patients with established COPD regarding the role of bacterial
products and point to a possible disease modifying role of SAEs.








Abbreviations: AEDS, atopic eczema/dermatitis syndrome; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity; GOLD, global Initiative for chronic obstructive lung disease; IgE, immunoglobulin E;
SAE, Staphylococcus aureus enterotoxins; SAE-IgE, IgE antibodies against SAE; SPA, staphylococcus-derived protein A; TCR, T-Cell
Receptor; TSST, toxic shock syndrome toxin
$-This work was supported by the Bundesministerium f .ur Bildung und Forschung (BMBF) Grant #01GC 9802/8 (Gernot Rohde), by the
Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Grant A 12/5-KV-K17 (Claus Bachert), by grant FWO A12/5-KV-K17 (Claus
Bachert), and by an unrestricted research grant from Aventis Pharma Germany.
*Corresponding author. Tel.: þ 49-234-3020; fax: þ 49-302-6420.
E-mail address: gernot.rohde@rub.de (G. Rohde).
0954-6111/$ - see front matter & 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2004.02.012
Respiratory Medicine (2004) 98, 858–864
Introduction
COPD is characterized by progressive airflow limita-
tion caused by chronic inflammation in the peripheral
airways and lung parenchyma.1 Infectious agents are
an important factor in the pathophysiology of COPD.
The most common pathogens recovered are viruses2
and bacteria.3 The most important bacteria found
during acute exacerbations of COPD are pneumococ-
ci, Haemophilus influenzae, Moraxella catarrhalis
and Staphylococcus aureus.4–6 Moreover, chronic
bacterial colonization in the lower respiratory tract
of patients with chronic bronchitis has been shown.7
Recent evidence suggests that Staphylococcus aureus
enterotoxins (SAE) could modify airway disease by
acting as superantigens.8 SAE are a group of high-
molecular weight pyrogenic proteins that have in
common an extremely potent stimulatory activity for
T-lymphocytes, including CD4þ , CD8þ , and gamma
deltaþ T-cells, of several species.9,10 Superantigens
exert this effect on the T-cells by cross-linking the
variable part on the beta chain of the T-cell receptor
(TCR) with MHC class II molecules on accessory or
target T-cells, outside the peptide-binding groove
area,11 although binding to MHC class I molecule has
also been observed in a MHC class II-negative
epidermal cell line.12 This leads to stimulation of up
to 20–25% of the naive T-cell population in a non-
specific way, compared with stimulation of only about
0.1% of the T-cell population via the conventional
allergen-specific MHC-restricted route utilizing both
TCR-Vaand b chains.13 Staphylococcal protein A (SPA)
as well as the SAE TSST-1 have also been demon-
strated to possess B-cell superantigen moieties,
inducing polyclonal IgE synthesis.14,15 In COPD,
CD8þ T-cells are found in elevated numbers in the
peripheral airways16 and their number correlates
with airflow limitation.17 It is therefore possible that
there may be an interaction of these CD8þ T-cells
with staphylococcal enterotoxins. Moreover, IgE anti-
bodies to SAE were found significantly more fre-
quently in severe difficult to treat asthma, which
shares some features with COPD, compared to
controls. These antibodies were linked to the severity
of inflammation, concentrations of IgE antibodies,
and corticosteroid dependence.8 Therefore we
sought to determine a possible role of bacterial
superantigens in COPD.
Patients and methods
Four different groups of patients were investi-
gated. Healthy controls were in generally good
health and had no respiratory symptoms. Spirome-
try was normal, they were non-smoking and the
skin prick test was negative to common allergens
(D. pteronyssinus, Alternaria tenuis, grass and
birch pollen, cat). They were recruited from the
personnel of the hospital. Smokers had smoked for
more than 10 pack years and were still active, and
had chronic symptoms like cough and phlegm but
did not report about dyspnea. The spirometry was
normal (FEV1480%, FEV1/FVC470%). This group
was recruited by the help of a newspaper adver-
tisement from the population of Bochum. There
was no history of COPD, allergic disease (asthma,
rhinitis or dermatitis), upper respiratory tract
infection in the previous month, use of any
systemic or topical medication in these two groups.
The third group were patients with stable COPD
hospitalized for other reasons than COPD. The
diagnosis of COPD was based on the GOLD criter-
ia.18 They were at least GOLD stage 2 and did not
have an exacerbation within the last 30 days prior
to hospital admission, and had no changes in
therapy within the last 14 days (including inhaled
and oral medication). The last group were exacer-
bated COPD patients, characterized by worsening
in dyspnoea, cough and expectoration,19 which
were hospitalized for acute exacerbation. There
were no limitations regarding the necessary med-
ication before admission. During hospitalization,
patients were treated with systemic corticosteroids
and most of the patients received a course of
antibiotic therapy. Exclusion criteria for both COPD
groups were bronchial asthma and dyspnea of other
origin (cardiovascular, broncho-pulmonary [e.g.
pneumonia, interstitial lung disorders], pleural, or
others [e.g. upper airways obstruction, neuromus-
cular, anemia]).
The study was approved by the Ethical Commit-
tee of the Ruhr-University of Bochum, Germany.
Written informed consent was obtained from all
subjects before inclusion into the study.
Data collection
Smoking habits and current medication were
recorded from all subjects.
Diagnostic Methods
Spirometry
Spirometric tests were performed using a Jaeger
Flowscreen device (E Jaeger, W.urzburg, Germany).
The best out of three trials was selected and data
were compared with reference values.20 Forced
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expiratory volume in 1 s (FEV1), before and after
inhalation of two puffs of salbutamol (200mg)
delivered by a metered dosed inhaler were assessed.
Phadiatop, total and specific IgE
Blood was allowed to clot at room temperature for
20–30min, centrifuged at 1500 g for 10min at 41C,
separated and stored in aliquots at 801C until
analysis. All supernatants and sera were assayed for
an IgE screening for inhalant allergens (Phadiatop),
total and specific IgE by the Uni-CAP system
(Pharmacia & Upjohn, Upsala, Sweden). Specific
IgE was determined for a mix of S. aureus
enterotoxins (SEA, SEC, and TSST-1) as described
before.8 No non-specific IgE reactivity to the SAE mix
ImmunoCAP was found for non-antibody active IgE (E
myeloma) at concentrations up to 1000 kU/l. Sam-
ples positive for IgE antibody to the SAE mix tested
negative to a control ImmunoCAP without allergen.
Statistical analysis
The primary objective of this study was to compare
the levels of IgE to SAE in healthy controls, smokers
and patients with and without acute exacerbation of
COPD. Secondary objectives were to correlate the
findings to clinical parameters. Continuous data
were checked for normal distribution using the
Kolmogorov–Smirnov test. The data were of non-
parametrical distribution and results were expressed
as median and range. Differences between groups
were assessed by Kruskal–Wallis test. To further
analyse significant differences between two indivi-
dual groups a pair wise comparison by two-sided
Mann–Whitney U-test was performed. The two-sided
Wilcoxon test was used for paired variables. For
discrete variables, frequencies and percentages
were reported and compared by w2 test or Fisher’s
exact test where appropriate. The Yates correction
procedure was applied to all comparisons. For
correlation analysis the Spearman–Rho coefficient
was calculated. All significance level were set to 5%.
Data were analysed and processed on SPSS Version
10.0 on a Windows 98 operating system.
Results
Patients
Eleven healthy controls, 16 smokers, 18 patients
with stable COPD and 54 patients with acute
exacerbation of COPD were included (Table 1).
None of the healthy controls, all of the smokers, 4/
18 (22%) of the stable COPD patients and 22/54
(41%) of the exacerbated COPD patients were
active smokers. The number of pack years ranged
from 35 to 43 in the latter three groups without
significant differences between the groups. Neither
healthy controls nor smokers received any medica-
tion. There were no significant differences between
stable and exacerbated COPD patients concerning
medication with inhaled or systemic steroids. The
FEV1 was normal in healthy controls and smokers,
whereas there was a significant reduction in
patients with stable COPD (52.9 [26.8–71.3]%pre-
dicted, Po0:001). FEV1 in exacerbated patients
was significantly further decreased compared to
stable patients (38.1 [16.8–79.5]%predicted,
Po0:001). None of the patients with COPD had a
reversibility in FEV1 of more than 15% predicted.
Phadiatop
IgE screening for inhalant allergens (Phadiatop) was
positive in 20% of healthy controls, in 28% of
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Table 1 Characteristics of the patients.
Healthy controls
(n ¼ 11)
Smokers (n ¼ 16) Stable COPD
(n ¼ 18)
AE-COPD (n ¼ 54)
Age Median [range] 28 [23–38] 48.5 [46–56] 67 [53–86] 69 [43–83]
Smoking n (%) 0 16 yes (100%) 4 no (22%) 7 no (13%)
10 ex (56%) 25 ex (46%)
4 yes (22%) 22 yes (41%)
Pack-Years Median [Range] 0 38 [15–92] 43 [1–80] 35 [1–88]
Inhaled and/or systemic
corticosteroids n(%)
0 0 13 (72%) 44 (82%)
FEV1%predicted Median
[Range]
99.0 [90.1–125.9] 98.4 [75.6–124] 52.9 [26.8–71.3] 38.1 [16.8–79.5]
Reversibility (%) Median
[Range]
n.d. n.d. 3.6 [-2.8–14.4] 0.0 [-22.9–13.9]
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patients with stable COPD and in 25% of patients
with exacerbated COPD without any significant
differences between these groups.
Total IgE
Total IgE levels of the COPD group as a whole were
not significantly higher than in healthy controls
(56.1 [5.3–2440] vs. 37.8 [8.4–236]kUA/l,
P ¼ 0:361). When healthy controls, smokers, pa-
tients with stable and exacerbated COPD were
analysed by Kruskal–Wallis test no significant
differences between the groups were detected
(P ¼ 0:163; Table 2 and Fig. 1).
IgE- antibodies to SAE
Only 1/10 controls (10%) and 1/16 smokers (6.3%)
had IgE to SAE compared to 7/18 patients with
stable COPD (38.9%) and 21/54 patients with
exacerbated COPD (38.9%). Smokers had signifi-
cantly less frequently IgE to SAE compared to
patients with stable COPD (P ¼ 0:043) and com-
pared to patients with exacerbated COPD
(P ¼ 0:031). When the absolute levels were ana-
lysed by Kruskal–Wallis, there were significantly
higher levels in both, the stable and the exacer-
bated COPD patients compared to either healthy
controls or smokers (Fig. 2).
Correlation of total IgE and SAE-IgE
There was a significant correlation between total
and specific IgE levels (r ¼ 0; 62; Po0:001) in the
COPD patients. However, six subjects demonstrated
increased total IgE of more than 200 kUA/l, but did
not show IgE antibodies to SAE, indicating that the
test was independent from total IgE levels, and
that other than the tested staphylococcal super-
antigens might be involved in some cases. This
correlation was not found in healthy controls or
smokers.
Effect of hospitalization on IgE levels to SAE
in AE-COPD patients
IgE levels to SAE were determined at admission to
and closely before discharge from the hospital in 44
AE-COPD patients (mean duration 15.5 [3–45]
days). SAE-IgE levels decreased significantly in
these patients during hospitalization (0.13 [0.05–
18.3]kUA/l vs. 0.05 [0.05–11]kUA/l, Po0:001).
Along with this decrease there was a significant
increase in FEV1 in these patients (38.1 [16.9–79.5]
vs. 51.6 [15–80]%predicted, Po0:001) and we
found an inverse correlation between these
changes (r ¼ 0:216; P ¼ 0:033).
Discussion
Similar to findings in unstable asthma8 we here
describe significantly higher serum levels of specific
IgE antibodies against staphylococcal enterotoxins
in COPD patients compared to healthy controls and
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Total IgE (kUA/I) Median [Range] 37.8 26.5 62.2 54.1
[8.4–236] [2.9–388] [7.4–1476] [5.3–2440]
IgE to SAE n pos./n total [%] 1/10 4/16 10/18 27/54
[10%] [25%] [56%] [50%]
















1=Healthy Control, 2=Smoker, 3=stable COPD,
4=exacerbated COPD
Figure 1 Serum levels of total IgE. Box-and-whisker
plot: the central box represents the values from the
lower to upper quartile (25–75 percentile), the middle
line the median and the whiskers the highest and lowest
value respectively exclusive outliers.
SAE-IgE in COPD 861
smokers. Regarding the clinical presentation of the
patients and the spirometric data showing no
reversibility of airflow obstruction after broncho-
dilator use, we are sure that none of our COPD
patients could have suffered from asthma. It is
important to notice that there were no significant
differences in total IgE antibody levels or in IgE to
common inhalant allergens (Phadiatop) between
healthy controls and patients with COPD. Moreover,
none of these subjects suffered from allergic
symptoms. This underlines the fact, that produc-
tion of IgE to SAE is of non-atopic origin, but rather
reflects the superantigen activity on B- and T-cells
as described before.11–15 Looking at the median age
of the four different groups one might argue that
aging may influence levels of IgE to SAE. However,
it is not probable that these differences in age play
a role in the differences in IgE to SAE-levels
reported. The main changes in the adaptive
immune system occur in the T-cells compart-
ment.21,22 Nevertheless changes both in the B-cell
germline-encoded repertoire and the age-asso-
ciated decrease in somatic hypermutation of the
B-cell antigen receptors are now known to be
critically affected by helper T-cell aging. But these
effects would rather cause a diminished antibody
production whereas we found increased antibodies
to SAE. Therefore this would cause a conservative
mistake rather underestimating the differences in
IgE to SAE-levels between the groups. Moreover the
B-cell number is strictly regulated and despite the
decreased output of B-cells by the bone marrow
does not decline during aging. Self-renewal of
peripheral B-cells is sufficient to assure the stability
of peripheral B-cell number.23 Therefore the
differences in age between the groups are not
responsible for the increase in IgE to SAE in patients
with COPD.
The levels of IgE to SAE were significantly
elevated not only in the exacerbated group but
also in patients with stable COPD. This may be an
expression of the bacterial colonization observed in
the lower airways in COPD including S. aureus.24
However, not the mere presence, but rather the
release of enterotoxins from staphylococcal strains
might be important. In other chronic diseases like
atopic eczema/dermatitis syndrome (AEDS) there is
much greater S. aureus colonization in the skin of
patients (80–100%) than in normal healthy subjects
(5–30%). S. aureus isolated from the skin of at least
65% of the AEDS patients secrete superantigens
SEA, SEB, SEC, SED and TSST-1, which penetrate the
epidermis and dermis after breakdown of the
epithelial barrier, where they interact with differ-
ent cells of the immune system, leading primarily
to a T-cell-dependent inflammation.25 Although S.
aureus is less frequently found in COPD, a similar
way of activation may be given in COPD. However,
the data presented here are only preliminary and
do not allow to conclude on a mechanism. Future
studies will have to address this issue. Interestingly,
in mice, staphylococcal enterotoxins have been
shown to induce lymphocyte-dependent airway
inflammation.26 CD8þ lymphocytes are found in
COPD in elevated numbers in the peripheral air-
ways16 and their number correlates with airflow
limitation.17 It is therefore possible that there may
be an activation of these CD8þ T-cells by staphy-
lococcal enterotoxins. In the patients with exacer-
bated COPD there was an inverse correlation
between levels of IgE to SAE and FEV1 during
hospitalization supporting this hypothesis.
A possible drawback of this study may be seen in
the lack of microbiologic data showing S. aureus
colonization and production of enterotoxins within
the lower airways, but S. aureus is often found as
part of the normal microflora of the human skin,
the upper respiratory tract, especially the vestibu-
lum nasi, and the intestinal tract. In patients with
COPD there is bacterial colonization also in the
lower airways including S. aureus.24 Moreover,
during exacerbations of COPD, S. aureus has been
found as a pathogen.5,6 Nevertheless there are no
prospective studies investigating staphylococcal
carriage in patients with COPD. However, there
are studies looking at nasal staphylococcal car-
riage. The nasal vestibule is the ecologic reservoir

























Figure 2 Serum levels of IgE to SAE. Box-and-whisker
plot. The central box represents the values from the
lower to upper quartile (25–75 percentile), the middle
line the median and the whiskers the highest and lowest
value respectively exclusive outliers. Arrows are drawn
between groups with significant differences.
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being permanent carriers.27 A large proportion of
the population (approximately 60%) harbours S.
aureus intermittently, and the strains change with
varying frequency. Notably, only a minority of
people (approximately 20%) almost never carries
S. aureus.27 The differences could be due to host
factors and/or to competition between members of
the nasal flora (e.g. Corynebacterium spp.).28
Indeed, a higher incidence of S. aureus colonization
of skin or mucous membranes may be due to
injuries (e.g.smoking), abnormal leukocyte func-
tion and inflammation (e.g. atopic dermatitis),
viral infections (e.g. influenza), metabolic abnorm-
alities (e.g. diabetes mellitus and uraemia) and
miscellaneous other conditions (e.g. malnutrition,
old age, malignancies, etc.).27 In elderly hospita-
lized patients 20%29 to 33%30 are concerned. Added
to the information given above it is very likely that
numbers are even higher in patients with COPD. We
think that IgE to SAEs found in serum actually are
induced by S. aureus localized in the lower airways
of these patients. Alternatively, the source of SAEs
may also be the nose and sinuses, and droplets from
the nose containing SAEs could be inhaled. How-
ever, it has been shown for other bacteria like
Streptococcus pneumoniae and Haemophilus influ-
enzae that elevated levels of specific IgE can be
found.31,32
In conclusion, this is the first study showing
elevated IgE antibodies directed against S. aureus
enterotoxins in the serum of patients with COPD,
serving as a marker for previous or current contact
of the immune system to SAEs. Our data indicate an
immunological reaction to superantigens as a
possible trigger of chronic inflammation in COPD,
which needs further study.
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